Advances in Metabolomics for Precision Medicine: From Biomarker Discovery to Clinical Applications: 2nd Edition
A special issue of Metabolites (ISSN 2218-1989). This special issue belongs to the section "Endocrinology and Clinical Metabolic Research".
Deadline for manuscript submissions: 30 November 2026 | Viewed by 876
Special Issue Editors
Interests: precision medicine; metabolomics; autoimmune diseases; infectious diseases
Special Issues, Collections and Topics in MDPI journals
Interests: cardiometabolic diseases; population health; endocrine diseases
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Although clinical chemistry analyses such as fasting plasma glucose, cholesterol, triglycerides, and the components of the basic and complete metabolic panels serve as the backbone for preliminary patient analyses, the development of more advanced tests means that they are beginning to be used to diagnose patients. Currently, standard assays such as the lipid panel which provides high-density lipoprotein (HDL), low-density lipoprotein (LDL), triglyceride, and cholesterol levels provide an overall assessment of the potential presence of a disease linked to lipid metabolism in patients. Metabolomics can provide additional information regarding a greater number of molecules and the speciation of molecules, which can provide additional insight into the presence of disease by identifying biochemical trajectories earlier in the disease onset process and providing additional insight into the presence of a specific disease. For example, metabolomics and lipidomic signatures not only provide cholesterol levels but also information on bile acids, free fatty acids, acylcarnitines, ketone bodies, sterols, steroid hormones, and higher-molecular-weight lipid species such as mono-, di-, and triacylglycerols, cholesterol esters, sphingolipids, and others. This more comprehensive assessment from a single, low-volume sample can provide insight into multiple different disease mechanisms and these same molecules can be leveraged to characterize therapeutic (medicinal and nutritional) interventions once patients are diagnosed and treated. Metabolomics can be applied to cardiometabolic diseases, hormonal dysfunction (e.g. thyroid diseases), neurological diseases, autoimmune diseases, diseases of the digestive system, and others. A patient’s metabolomic profile is not just driven by their genotype, but also by their nutritional intake and environmental and lifestyle choices. Understanding the implications of each of these contributors is of central importance to understanding a patient’s phenotype, not only to monitor human health but also to identify new biomarkers of disease and to monitor therapeutic interventions for those diseases.
This Special Issue of Metabolites entitled “Advances in Metabolomics for Precision Medicine: From Biomarker Discovery to Clinical Applications: 2nd Edition” will be dedicated to identifying and addressing the most current challenges and successes in utilizing metabolomics independently or alongside other ‘omics’ technologies for diagnosing diseases and following patients post intervention to treat their disease. In addition to clinical studies, basic research including animal models and cell culture studies will also be included to provide a robust picture of the latest results in the field. New bioinformatics approaches for data analysis and tools to analyze large data sets are of interest and will also be considered for this Special Issue.
Dr. Adam D. Kennedy
Dr. Greg Michelotti
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Metabolites is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- metabolomics
- precision medicine
- clinical disease
- biomarkers
- therapeutics
- clinical metabolomics
- nutrition
- functional medicine
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
